273 related articles for article (PubMed ID: 12505689)
41. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
42. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes.
Savinainen JR; Järvinen T; Laine K; Laitinen JT
Br J Pharmacol; 2001 Oct; 134(3):664-72. PubMed ID: 11588122
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular pharmacology of anandamide.
Högestätt ED; Zygmunt PM
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):343-51. PubMed ID: 12052048
[TBL] [Abstract][Full Text] [Related]
44. The endocannabinoid system as a target for therapeutic drugs.
Piomelli D; Giuffrida A; Calignano A; Rodríguez de Fonseca F
Trends Pharmacol Sci; 2000 Jun; 21(6):218-24. PubMed ID: 10838609
[TBL] [Abstract][Full Text] [Related]
45. Cannabinoid receptors and their endogenous agonist, anandamide.
Axelrod J; Felder CC
Neurochem Res; 1998 May; 23(5):575-81. PubMed ID: 9566594
[TBL] [Abstract][Full Text] [Related]
46. Anandamide may mediate sleep induction.
Mechoulam R; Fride E; Hanus L; Sheskin T; Bisogno T; Di Marzo V; Bayewitch M; Vogel Z
Nature; 1997 Sep; 389(6646):25-6. PubMed ID: 9288961
[No Abstract] [Full Text] [Related]
47. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
[TBL] [Abstract][Full Text] [Related]
48. [Cannabinoids, cannabinoid receptor and immune response].
Yan MS; Lian ML; Huang JS
Sheng Li Ke Xue Jin Zhan; 2000 Jul; 31(3):261-4. PubMed ID: 12545719
[No Abstract] [Full Text] [Related]
49. Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors.
Christopoulos A; Wilson K
Brain Res; 2001 Oct; 915(1):70-8. PubMed ID: 11578621
[TBL] [Abstract][Full Text] [Related]
50. Endocannabinoid immune and vascular signaling.
Stefano GB
Acta Pharmacol Sin; 2000 Dec; 21(12):1071-81. PubMed ID: 11603279
[No Abstract] [Full Text] [Related]
51. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid.
Fowler CJ; Jonsson KO; Andersson A; Juntunen J; Järvinen T; Vandevoorde S; Lambert DM; Jerman JC; Smart D
Biochem Pharmacol; 2003 Sep; 66(5):757-67. PubMed ID: 12948856
[TBL] [Abstract][Full Text] [Related]
52. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart.
Bouchard JF; Lépicier P; Lamontagne D
Life Sci; 2003 Mar; 72(16):1859-70. PubMed ID: 12586223
[TBL] [Abstract][Full Text] [Related]
53. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.
Bátkai S; Járai Z; Wagner JA; Goparaju SK; Varga K; Liu J; Wang L; Mirshahi F; Khanolkar AD; Makriyannis A; Urbaschek R; Garcia N; Sanyal AJ; Kunos G
Nat Med; 2001 Jul; 7(7):827-32. PubMed ID: 11433348
[TBL] [Abstract][Full Text] [Related]
54. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
55. 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor.
Kagota S; Yamaguchi Y; Nakamura K; Sugiura T; Waku K; Kunitomo M
Eur J Pharmacol; 2001 Mar; 415(2-3):233-8. PubMed ID: 11275004
[TBL] [Abstract][Full Text] [Related]
56. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function.
Ralevic V; Kendall DA; Randall MD; Smart D
Life Sci; 2002 Oct; 71(22):2577-94. PubMed ID: 12354577
[TBL] [Abstract][Full Text] [Related]
57. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells.
Sugiura T; Kodaka T; Kondo S; Tonegawa T; Nakane S; Kishimoto S; Yamashita A; Waku K
Biochem Biophys Res Commun; 1996 Dec; 229(1):58-64. PubMed ID: 8954083
[TBL] [Abstract][Full Text] [Related]
58. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon.
Smid SD; Bjorklund CK; Svensson KM; Heigis S; Revesz A
Eur J Pharmacol; 2007 Dec; 575(1-3):168-76. PubMed ID: 17706636
[TBL] [Abstract][Full Text] [Related]
59. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Farquhar-Smith WP; Jaggar SI; Rice AS
Pain; 2002 May; 97(1-2):11-21. PubMed ID: 12031775
[TBL] [Abstract][Full Text] [Related]
60. Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery.
Randall MD; Kendall DA
Eur J Pharmacol; 1998 Apr; 346(1):51-3. PubMed ID: 9617751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
